Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340699 | 0.81 | GRB2 (0.49) | GRB2CAPN1CTSBNTSR2NTSR1 | |
| SCHEMBL16351201 | 0.78 | GRB2 (0.47) | GRB2CAPN1NTSR2NTSR1SLC6A2 | |
| SCHEMBL29801717 | 0.77 | GRB2 (0.51) | GRB2NTSR2NTSR1XIAPAPLNR | |
| SCHEMBL29801939 | 0.77 | ACE (0.50) | GRB2NTSR2NTSR1XIAPF2 | |
| SCHEMBL29392602 | 0.77 | GRB2 (0.66) | GRB2CAPN1NTSR2NTSR1APLNR | |
| SCHEMBL16351228 | 0.77 | RAMP3 (0.41) | GRB2CAPN1APLNR | |
| SCHEMBL16351238 | 0.76 | F2 (0.42) | GRB2CAPN1CTSBNTSR2NTSR1 | |
| SCHEMBL13084631 | 0.76 | GRB2 (0.50) | GRB2CAPN1NTSR2NTSR1F2 | |
| SCHEMBL12261069 | 0.76 | GRB2 (0.50) | GRB2CAPN1NTSR2NTSR1F2 | |
| SCHEMBL12237919 | 0.76 | GRB2 (0.50) | GRB2CAPN1NTSR2NTSR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO SUISSE S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | GRB2 756/4885CAPN1 1439/4885CTSB 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.